Gproan Biotech

Gproan Biotech is a clinical-stage biotechnology company headquartered in Beijing, China, focused on the development of mRNA-based vaccines and therapeutics. The company utilizes a proprietary mRNA design and synthesis platform alongside advanced lipid nanoparticle (LNP) delivery technology. Its primary pipeline targets include infectious diseases such as COVID-19, shingles, and respiratory syncytial virus (RSV), as well as various oncology indications through therapeutic cancer vaccines. Gproan maintains integrated capabilities spanning from early-stage discovery to pilot-scale manufacturing. The company is recognized for its independent intellectual property in LNP delivery systems, which are critical for the stability and efficacy of mRNA medicines.